By Eli LillyLearning Objectives
- Understand what TuneLab offers biotech partners and how it works
- Understand federated learning and why it lets Lilly share models without sharing data
- Evaluate why TuneLab is a landmark "productized adopter" example
What Is Lilly TuneLab?
Lilly TuneLab is a drug-discovery platform from Eli Lilly that gives external biotech companies access to Lilly's AI models for small-molecule and antibody discovery. What makes it notable is the source of the models' power: they are trained on decades of Lilly's proprietary experimental data — the kind of large, high-quality dataset that individual biotechs cannot build on their own. Through TuneLab, a smaller company can run its molecules against models informed by that data to predict properties and prioritize candidates, effectively renting a slice of a pharma giant's accumulated knowledge.
The clever part is how Lilly shares without giving away its crown jewels. TuneLab uses federated learning, a technique where a model can be trained on or applied to data without the underlying data ever being exposed — so partners benefit from Lilly's models while Lilly's raw data stays private, and partners' molecules stay private too. In early 2026 Lilly expanded TuneLab with integrations into common biotech tools, including Schrödinger's LiveDesign, Benchling and Revvity's Signals platform, reaching a large base of biotech customers. In June 2026 it began offering an outside company's models too: select TuneLab biotechs can try Chai Discovery's miniprotein design suite on a free-trial basis. TuneLab is the clearest example of the "productized adopter" pattern: a pharma incumbent that both uses AI internally at scale and, selectively, sells access to what it has built.
💡Key Concept
Federated learning: A method that lets a model learn from or serve data without moving or exposing that data. It is what allows TuneLab to share the value of Lilly's proprietary datasets with partners while keeping the underlying data — on both sides — private.
📝Note
The "productized adopter": Most large companies are AI adopters (using AI internally) or AI vendors (selling AI products). TuneLab makes Lilly both — it turned an internal capability, trained on data only a pharma giant could accumulate, into an outward-facing platform for biotech partners.
🎯Tip
Visit Lilly TuneLab: tunelab.lilly.com — a platform for biotech partners, delivered via federated learning.
Pricing
TuneLab is a partner platform for biotech companies rather than a self-serve product with published pricing; access is arranged through partnership and subscription agreements, with the value proposition being access to models trained on Lilly's proprietary data.
- Access to Lilly AI models
- Small-molecule and antibody discovery
- Federated learning (data stays private)
- Schrödinger LiveDesign integration
- Benchling integration
- Revvity Signals (co-funded access for selected biotechs)
- Chai Discovery miniprotein design suite
- Candidates generated in silico in hours
- Deployment license needed for further preclinical work
Core Features
Access to Proprietary-Data Models
Lets biotech partners apply AI models trained on decades of Lilly's experimental data to their own discovery programs — a data advantage smaller companies cannot replicate alone.
Federated Learning
Shares model value without exposing raw data on either side, so Lilly's datasets and partners' molecules both stay private.
Small-Molecule and Antibody Support
Covers models for both small-molecule and antibody discovery, two of the major modalities in modern drug development.
Tool Integrations
Integrates with widely used biotech platforms — including Schrödinger's LiveDesign, Benchling and Revvity's Signals — so partners can use TuneLab within existing workflows. Through Revvity, announced in January 2026, Lilly and Revvity jointly fund access for selected participants, including software and modeling credits.
Partner Models: Chai Discovery (June 2026)
TuneLab now carries models from outside Lilly as well. Under a June 2026 agreement, select participating biotechs can use Chai Discovery's miniprotein design suite on a free-trial basis, generating candidate designs in silico within hours instead of screening physical libraries. Taking a design further into preclinical work requires a deployment license from Chai. This sits alongside Lilly's separate biologics collaboration with Chai, signed in January 2026.
Strengths
- Access to a rare data advantage — models trained on decades of Lilly's proprietary data
- Privacy-preserving — federated learning keeps both sides' data private
- Two modalities — small-molecule and antibody discovery
- Workflow-native — integrations with Schrödinger LiveDesign, Benchling and Revvity Signals
- Outside models too — Chai Discovery's miniprotein design suite on free trial for select participants
- A landmark case — a pharma incumbent productizing internal AI for outside partners
Limitations and Considerations
- For biotech partners, not general users — a partnership platform, not self-serve software
- Value tied to Lilly's data domains — most useful where Lilly's data is relevant
- Predictions are hypotheses — model outputs still require experimental validation
- Partnership terms matter — access, scope, and data rights are negotiated
- Long path to the clinic — better candidates still face years of development
Best Use Cases
| Use Case | Why TuneLab Fits | Caveat |
|---|---|---|
| Biotech small-molecule discovery | Models trained on Lilly's proprietary data | Predictions need experimental validation |
| Antibody discovery programs | Antibody-focused model access | Value depends on data relevance |
| Prioritizing candidates | Predict properties to focus resources | A hypothesis-generation tool |
| Using existing discovery tools | Integrates with LiveDesign and Benchling | Partnership access required |
Key Takeaways
- Lilly TuneLab gives biotech companies access to Eli Lilly's AI models for small-molecule and antibody discovery, trained on decades of proprietary data
- Federated learning lets Lilly share model value while keeping its raw data — and partners' molecules — private
- Early-2026 integrations with Schrödinger LiveDesign, Benchling and Revvity Signals embedded TuneLab into common biotech workflows, and since June 2026 select participants can trial Chai Discovery's miniprotein design models on the platform
- It is the clearest example of the "productized adopter": a pharma incumbent both using AI internally and selling access to what it built
- Model outputs are hypotheses that still require experimental validation, and access is arranged through biotech partnerships
